| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5574536 | Journal of Stroke and Cerebrovascular Diseases | 2017 | 7 Pages |
Abstract
LAAC followed by single antiplatelet therapy is feasible as an alternative to oral anticoagulation in high-risk patients with previous ICH, with an acceptable periprocedural risk. Longer follow-up in a larger number of patients will be needed to establish the effectiveness of LAAC relative to direct oral anticoagulants.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Clinical Neurology
Authors
Pauline MD, Jean-Benoît MD, PHD, Xavier MD, Stéphanie MD, Nathanael MD, Zakaria MD, Stéphane MD, Sabrina MD, Mathilde MD, François MD, Igor MD,